Literature DB >> 15905495

Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant.

Ciriana Orabona1, Maria Laura Belladonna, Carmine Vacca, Roberta Bianchi, Francesca Fallarino, Claudia Volpi, Stefania Gizzi, Maria Cristina Fioretti, Ursula Grohmann, Paolo Puccetti.   

Abstract

CTLA-4-Ig and CD28-Ig are both agonist ligands of B7 coreceptor molecules on mouse dendritic cells (DCs), yet they bias the downstream response in opposite directions, and CTLA-4-Ig promotes tolerance, whereas CD28-Ig favors the onset of immunity. Although B7 engagement by either ligand leads to a mixed cytokine response, a dominant IL-6 production in response to CD28-Ig prevents the IFN-gamma-driven induction of immunosuppressive tryptophan catabolism mediated by IDO. In the present study, we show that silencing the expression of suppressor of cytokine signaling 3 (SOCS3) in DCs by RNA interference renders CD28-Ig capable of activating IDO, likely as a result of unrestrained IFN-gamma signaling and IFN-gamma-like actions of IL-6. Thus, in the absence of SOCS3, CD28-Ig becomes immunosuppressive and mimics the action of CTLA-4-Ig on tryptophan catabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905495     DOI: 10.4049/jimmunol.174.11.6582

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.

Authors:  Tracy L McGaha; Lei Huang; Henrique Lemos; Richard Metz; Mario Mautino; George C Prendergast; Andrew L Mellor
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

Review 2.  Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege.

Authors:  Lei Huang; Babak Baban; Burles A Johnson; Andrew L Mellor
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

3.  IDO is a nodal pathogenic driver of lung cancer and metastasis development.

Authors:  Courtney Smith; Mee Young Chang; Katherine H Parker; Daniel W Beury; James B DuHadaway; Hollie E Flick; Janette Boulden; Erika Sutanto-Ward; Alejandro Peralta Soler; Lisa D Laury-Kleintop; Laura Mandik-Nayak; Richard Metz; Suzanne Ostrand-Rosenberg; George C Prendergast; Alexander J Muller
Journal:  Cancer Discov       Date:  2012-07-19       Impact factor: 39.397

4.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells.

Authors:  Maria T Pallotta; Ciriana Orabona; Claudia Volpi; Carmine Vacca; Maria L Belladonna; Roberta Bianchi; Giuseppe Servillo; Cinzia Brunacci; Mario Calvitti; Silvio Bicciato; Emilia M C Mazza; Louis Boon; Fabio Grassi; Maria C Fioretti; Francesca Fallarino; Paolo Puccetti; Ursula Grohmann
Journal:  Nat Immunol       Date:  2011-07-31       Impact factor: 25.606

Review 5.  Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Authors:  George C Prendergast; Courtney Smith; Sunil Thomas; Laura Mandik-Nayak; Lisa Laury-Kleintop; Richard Metz; Alexander J Muller
Journal:  Cancer Immunol Immunother       Date:  2014-04-08       Impact factor: 6.968

Review 6.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

7.  Allostimulatory activity of bone marrow-derived plasmacytoid dendritic cells is independent of indoleamine dioxygenase but regulated by inducible costimulator ligand expression.

Authors:  Bridget L Colvin; Tina L Sumpter; Daisuke Tokita; Jennifer Salati; Andrew L Mellor; Angus W Thomson
Journal:  Hum Immunol       Date:  2009-02-03       Impact factor: 2.850

8.  Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO.

Authors:  Tina L Sumpter; Anil Dangi; Benjamin M Matta; Chao Huang; Donna B Stolz; Yoram Vodovotz; Angus W Thomson; Chandrashekhar R Gandhi
Journal:  J Immunol       Date:  2012-09-07       Impact factor: 5.422

9.  SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis.

Authors:  Ciriana Orabona; Maria T Pallotta; Claudia Volpi; Francesca Fallarino; Carmine Vacca; Roberta Bianchi; Maria L Belladonna; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

Review 10.  T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.

Authors:  David J Kahler; Andrew L Mellor
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.